- AVTE Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
8-K Filing Data
Aerovate Therapeutics (AVTE) 8-K17 Jun 24AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied dosesFinancial data
Company Profile